1st Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$2,170,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

10 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Data Exclusivity Intellectual Property Issues in Response to coronavirus Patents Section 101

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Management & Budget (OMB); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); White House Office; SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC)

Budget/Appropriations BUD

Biosimilars Drug Pricing Fiscal year 2022 Appropriations H.R.1, For the People Act of 2021 H.R.1319, American Rescue Plan Act of 2021 Importation Value of Medicine

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Veterans Affairs, Dept of (VA); SENATE; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); State, Dept of (DOS); White House Office; Office of Management & Budget (OMB)

Bills named: H.R. 1319 (117th), H.R. 1 (117th)

Labor Issues/Antitrust/Workplace LBR

Anti-Trust Reform

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
COURTNEY PIRON —

Contacted: Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; State, Dept of (DOS); U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); White House Office; Health & Human Services, Dept of (HHS)

Science/Technology SCI

Artificial intelligence Data and digital technologies

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
SHELLY MUI-LIPNIK —
COURTNEY PIRON —

Contacted: U.S. Trade Representative (USTR); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; White House Office; State, Dept of (DOS); SENATE; Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); Office of Management & Budget (OMB)

Foreign Relations FOR

CFIUS Reform Foreign Agents Registration Act (FARA) Reform

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SHELLY MUI-LIPNIK —
COURTNEY PIRON —

Contacted: SENATE; Veterans Affairs, Dept of (VA); White House Office; Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); State, Dept of (DOS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); U.S. Trade Representative (USTR)

Trade (domestic/foreign) TRD

Access to Medicines Issues Biopharmaceutical Innovation Policies CFIUS China Agreement Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues Intellectual property International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Sub-standards Medicines Supply chain and China Task Force policy issues Tariffs Trade Policy UK Agreement USMCA USTR Special 301 Report/National Trade Estimate WTO IP Waiver

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: U.S. Trade Representative (USTR); SENATE; State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Office of Management & Budget (OMB); White House Office; Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Base Erosion Anti-Abuse Tax (BEAT) OECD Digital Tax Orphan Drug Tax Pharmaceutical supply chain incentives Thin Capitalization Rules 163(j) U.S. Corporate Tax

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Office of Management & Budget (OMB); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Veterans Affairs, Dept of (VA); Commerce, Dept of (DOC); White House Office; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

340B Drug Discount Program AMP Cap Biosimilar approval and reimbursement policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions BLOCKING Act Buy American and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Cell, gene and radioligand therapies COVID-19 Cures 2.0 Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and conterfeiting policy issues Drug shortages policy issues Drug vial size policy issues FDA modernization policy issues Foreign manufacturing policy issues FY 2022 Labor-HHS Appropriations Medicaid Generics Penalty Fix Medicaid Payment Reform Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Part B Home Infusion Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain Priority Review Voucher (PRV) Transparency policy issues H.R. 1873/S. 164: Advancing Education on Biosimilars Act of 2021 Pharmaceutical Regulatory Policy Issues Defense Production Act (DPA) policy issues Executive Order 14017, Americas Supply Chains (February 24, 2021) Executive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020) Interim Final Rule with comment period; Most Favored Nation (MFN) Model Executive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020)

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
SARAH HALLER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SHELLY MUI-LIPNIK —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Office of Management & Budget (OMB); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); State, Dept of (DOS); SENATE; White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1873 (117th), S. 164 (117th)

Veterans VET

Health care collaboration opportunities

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: Veterans Affairs, Dept of (VA); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); SENATE

Medicare/Medicaid MMM

AMP Cap Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues Tenncare III 1115 Medicaid Demonstration - Closed formulary issues S.2543: Prescription Drug Pricing Reduction Act of 2019 [116th Congress] H.R. 3: Lower Drug Costs Now Act of 2019 [116th Congress] H.R. 19: Lower Costs, More Cures Act of 2019 [116th Congress] S. 386/H.R. 1227: Medicare-X Choice Act of 2021

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS); SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); White House Office; U.S. Trade Representative (USTR)

Bills named: S. 386 (117th), H.R. 19 (117th), H.R. 3 (117th), H.R. 1227 (117th), S. 2543 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.